Latest News

New guidance on use of sNfL in practice

 

An international panel of experts in conjunction with the Consortium of MS Centers (CMSC) has developed recommendations on the use of neurofilament-light chain (NfL) as a biomarker of disease activity in multiple sclerosis (Freedman et al. eBioMedicine 2024;101:104970). Read More

New developments in epilepsy: focus on cenobamate

 

Cenobamate received Health Canada authorization last year as adjunctive therapy for patients with partial-onset seizures who are not adequately controlled with conventional therapies. The drug acts as a sodium channel blocker through selection inhibition of the persistent sodium current, and as a GABAA receptor modulator. Read More